AR109293A1 - IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS - Google Patents
IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUSInfo
- Publication number
- AR109293A1 AR109293A1 ARP170102210A ARP170102210A AR109293A1 AR 109293 A1 AR109293 A1 AR 109293A1 AR P170102210 A ARP170102210 A AR P170102210A AR P170102210 A ARP170102210 A AR P170102210A AR 109293 A1 AR109293 A1 AR 109293A1
- Authority
- AR
- Argentina
- Prior art keywords
- hbv
- agents
- hepatitis
- disclosed
- gene expression
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se dan a conocer composiciones y métodos para la inhibición de la expresión génica del virus de la Hepatitis B. Se dan a conocer agentes de interferencia de ARN (iARN) para la inhibición de la expresión de genes de virus de la Hepatitis B. Los agentes iARN VHB que se describen en la presente memoria pueden dirigirse a células, tales como hepatocitos, por ejemplo, utilizando ligandos de orientación conjugados. También se dan a conocer composiciones farmacéuticas que comprenden uno o más agentes iARN VHB opcionalmente con uno o más agentes terapéuticos adicionales. La entrega de los agentes iARN VHB descritos al hígado infectado in vivo permite la inhibición de la expresión génica de VHB y el tratamiento de enfermedades y condiciones asociadas con la infección por VHB.Compositions and methods for the inhibition of Hepatitis B virus gene expression are disclosed. RNA interference agents (RNAI) for the inhibition of Hepatitis B virus gene expression are disclosed. HBV iRNA described herein can be directed to cells, such as hepatocytes, for example, using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV iRNA agents optionally with one or more additional therapeutic agents are also disclosed. The delivery of the HBV iRNA agents described to the infected liver in vivo allows inhibition of HBV gene expression and the treatment of diseases and conditions associated with HBV infection.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662370754P | 2016-08-04 | 2016-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109293A1 true AR109293A1 (en) | 2018-11-14 |
Family
ID=64498538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102210A AR109293A1 (en) | 2016-08-04 | 2017-08-04 | IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR109293A1 (en) |
-
2017
- 2017-08-04 AR ARP170102210A patent/AR109293A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19015395A (en) | IRNA AGENTS FOR INFECTION CAUSED BY HEPATITIS B VIRUS | |
WO2017027350A3 (en) | Rnai therapy for hepatitis b virus infection | |
AR118719A2 (en) | OLIGONUCLEOTIDES TO REDUCE THE EXPRESSION OF PD-L1 | |
CY1125263T1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA | |
CL2017000780A1 (en) | Compositions and methods to silence the expression of the hepatitis b gene virus | |
PE20170262A1 (en) | OLIGOMERS AND CONJUGATES OF OLIGOMERS | |
JOP20210208A1 (en) | Rnai agents for hepatitis b virus infection | |
EA201692318A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE ALPHA-1-ANTITRIPSINE GENE | |
MX2015014816A (en) | Microrna compounds and methods for modulating mir-122. | |
AR109293A1 (en) | IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS | |
BR112014030623A2 (en) | composition, combination and their uses | |
EA201990427A1 (en) | RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUS | |
AR105611A1 (en) | RNAi THERAPY FOR HEPATITIS B VIRUS INFECTION | |
AR113454A1 (en) | IARN AGENTS AND COMPOSITIONS TO INHIBIT RECIPIENT EXPRESSION OF ASIALOGLYCOPROTEIN 1 | |
EA202192191A1 (en) | RNAi AGENTS AGAINST HEPATITIS B VIRUS INFECTION | |
CL2022002496A1 (en) | iRNA agents for infection caused by hepatitis b virus (divisional application 201900278) | |
AR106227A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE GENE EXPRESSION OF THE APO APOLIPOPROTEIN GENE (a) (LPA) | |
AR102614A1 (en) | HEPATITIS D VIRUS (HDV) RNAi COMPOSITIONS AND METHODS FOR USE |